New drug before surgery may keep prostate cancer at bay
NCT ID NCT06014255
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests whether giving the drug enoblituzumab for 12 weeks before prostate removal surgery can help prevent cancer from coming back in men with high-risk localized prostate cancer. About 219 men will be randomly assigned to receive either the drug or standard care. The main goal is to see if the drug improves how long men stay cancer-free after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21205, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Northewestern University
Chicago, Illinois, 60611, United States
-
University of Minnesota
Minneapolis, Minnesota, 55414, United States
-
XCancer - Omaha, LLC
Omaha, Nebraska, 68130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A surgical tweak may speed bladder control recovery after prostate removal
- Smarter prostate cancer screening: a blood test that may cut unnecessary biopsies
- Glow-in-the-dark dye may help surgeons spot hidden prostate cancer cells
- Blood DNA fragments and MRI join forces to spot hidden prostate cancer
- Can an AI agent match expert urologists? a major test begins
- Pumping iron to fight cancer's hidden immune toll